The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Slides:



Advertisements
Similar presentations
Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck
Advertisements

Bladder Cancer: A New Era in Treatment
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Evolving Paradigms in Recurrent/Metastatic SCCHN
Immunotherapies: Key Considerations in the Identification and Management of irAEs.
A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.
Program Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Gastrointestinal Cancers.
Advanced NSCLC Without Actionable Mutations
Fundamental Concepts in the Diagnosis of Advanced NSCLC
State of the Art in HCC: Immune Checkpoint Modulation
Case Studies.
New Patient Journeys in Non-small cell lung cancer
Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.
Progression After Cancer Immunotherapy in Advanced NSCLC
Introduction to Checkpoint Inhibitors
Spotlight on Immuno-Oncology in Melanoma
Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.
Updates in Lung Cancer: Insights From Vienna
Optimizing the Treatment of Recurrent/Metastatic SCCHN
The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.
Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.
Activity Goals. Activity Goals Discussion Topics.
Program Goals Introduction Case 1: A 44-Year-Old Woman.
The Evolving Role of Immunotherapy in NSCLC
Locally Advanced NSCLC Implementing Innovation
Optimizing Management of Advanced Bladder Cancer
Checkpoint Inhibition
Basics of Immunotherapy Potential Therapeutic Targets.
The Nurse View: Top Ten Things to Know About Immune-Mediated Adverse Events.
Advanced Lung Cancers: What's on the Horizon?
The Emerging Role of Immunotherapy in Hodgkin Lymphoma
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Immunotherapy for cSCC
Advancing Care in Genitourinary Cancer: Perspectives From Chicago
Evolving Concepts in the Management of Head and Neck Cancers
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Immune Checkpoint Inhibitors in Lung Cancer
Locally Advanced Lung Cancer
Advances in Gastrointestinal Cancers
Patient-Centered Management in Advanced Non-Small Cell Lung Cancer
Practical Guidance on the Management of Pan-Negative NSCLC
Challenges and Opportunities
Preparing for Checkpoint Inhibitors in Breast Cancer
This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.
Novel Concepts in the Management of RCC
Debates and Dilemmas, Part 1
From Adjuvant to Metastatic in Melanoma
Strengthening Lung Cancer Team Connections to Improve Outcomes With Immunotherapy.
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC
The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition
Checkpoint Inhibitors in First-Line Advanced NSCLC
Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.
The Nurse View: Spotlight on EGFR-Mutated NSCLC
A Pharmacist's Guide to Safety and Use of Immune Checkpoint Inhibitors
Going Beyond EXTREME in Head and Neck Cancer
Moving Care Forward in Advanced Gastric Cancer
Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.
New Options for the Treatment of Hepatocellular Carcinoma
MSI.
Current Status of Biomarkers for Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitors in Lung Cancer
Combining Immunotherapy and Chemotherapy in NSCLC
The Nurse View.
Recent Developments in the Treatment of Advanced and Metastatic RCC
Overview of irAEs. Management of Immune-Related Adverse Events for Patients Receiving Checkpoint Inhibitor Therapy.
Interprofessional Approach to Managing Adverse Events of PI3K Inhibitors.
Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer.
Presentation transcript:

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC

Checkpoint Inhibitors Approved in NSCLC

Immunotherapy vs Chemotherapy

Overview of Immune Regulation

Basics of Immunotherapy

CheckMate Trial Design

KEYNOTE Trial Design

Outcomes With Pembrolizumab

KEYNOTE-024 Trial Design

OAK Trial Design

Most Common TRAEs With Immunotherapy

Management of AEs

Grading of AEs

Management of irAEs Based on Grade

Management of Diarrhea/Colitis

Management of Pneumonitis

Management of Steroid-Refractory irAEs

Restarting Immunotherapy

Management of Hypothyroidism

Importance of Patient Education

The Future of Immunotherapy

Key Takeaways

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.